Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Exclusion Criteria

• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •GOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •SGOT ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •Renal
• •Creatinine ≤ 1.5 times ULN
• •Cardiovascular
• •No uncontrolled hypertension
• •No unstable angina
• •No congestive heart failure
• •No uncontrolled arrhythmias within the past 6 months
• •No other significant cardiac disease
• •Neurologic
• •No uncontrolled seizure disorder
• •No active neurological disease
• •No neuropathy \> grade 1
• •Other
• •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •No active infection requiring antibiotics
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior anti-epidermal growth factor receptor (EGFR) antibody therapy
• •No prior chimerized or murine monoclonal antibody therapy
• •At least 3 weeks since prior biologic or immunologic therapy for the malignancy
• •Chemotherapy
• •See Disease Characteristics
• •Recovered from prior chemotherapy
• •No prior cytotoxic chemotherapy for recurrent disease, including retreatment with initial chemotherapy regimens
• •Endocrine therapy
• •At least 1 week since prior hormonal therapy for the malignancy
• •Concurrent hormone replacement therapy allowed
• •Radiotherapy
• •See Disease Characteristics
• •Recovered from prior radiotherapy
• •No prior radiotherapy to \> 25% of bone marrow-bearing areas
• •Surgery
• •More than 30 days since prior major surgery and recovered
• •* Diagnostic biopsy not considered major surgery
• •Other
• •At least 3 weeks since other prior therapy for the malignancy
• •No prior tyrosine kinase inhibitors that target the EGFR pathway
• •No prior cancer treatment that would preclude study treatment
• •No other concurrent investigational agents